The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

V. De Stefano, B. Rocca, A. Tosetto, D. Soldati, G. Petrucci, E. Beggiato, I. Bertozzi, S. Betti, G. Carli, M. Carpenedo, D. Cattaneo, V. Cavalca, A. Dragani, E. Elli, G. Finazzi, A. Iurlo, G. Lanzarone, L. Lissandrini, F. Palandri, C. Paoli & 13 others A. Rambaldi, P. Ranalli, M. L. Randi, A. Ricco, E. Rossi, M. Ruggeri, G. Specchia, A. Timillero, L. Turnu, N. Vianelli, A. M. Vannucchi, F. Rodeghiero, C. Patrono

Research output: Contribution to journalArticle

Abstract

Once-daily (od), low-dose aspirin (75-100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.
Original languageEnglish
Pages (from-to)3
Number of pages1
JournalBlood Cancer Journal
Volume8
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Essential Thrombocythemia
Thromboxane B2
Aspirin
Serum
Biomarkers
Blood Platelets
Cyclooxygenase 1
Polycythemia Vera
Thromboxane A2
Epoprostenol
Multicenter Studies
Blood Vessels
Placebos
Exercise

Cite this

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. / Stefano, V. De; Rocca, B.; Tosetto, A.; Soldati, D.; Petrucci, G.; Beggiato, E.; Bertozzi, I.; Betti, S.; Carli, G.; Carpenedo, M.; Cattaneo, D.; Cavalca, V.; Dragani, A.; Elli, E.; Finazzi, G.; Iurlo, A.; Lanzarone, G.; Lissandrini, L.; Palandri, F.; Paoli, C.; Rambaldi, A.; Ranalli, P.; Randi, M. L.; Ricco, A.; Rossi, E.; Ruggeri, M.; Specchia, G.; Timillero, A.; Turnu, L.; Vianelli, N.; Vannucchi, A. M.; Rodeghiero, F.; Patrono, C.

In: Blood Cancer Journal, Vol. 8, No. 6, 01.06.2018, p. 3.

Research output: Contribution to journalArticle

Stefano, VD, Rocca, B, Tosetto, A, Soldati, D, Petrucci, G, Beggiato, E, Bertozzi, I, Betti, S, Carli, G, Carpenedo, M, Cattaneo, D, Cavalca, V, Dragani, A, Elli, E, Finazzi, G, Iurlo, A, Lanzarone, G, Lissandrini, L, Palandri, F, Paoli, C, Rambaldi, A, Ranalli, P, Randi, ML, Ricco, A, Rossi, E, Ruggeri, M, Specchia, G, Timillero, A, Turnu, L, Vianelli, N, Vannucchi, AM, Rodeghiero, F & Patrono, C 2018, 'The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting', Blood Cancer Journal, vol. 8, no. 6, pp. 3. https://doi.org/10.1038/s41408-018-0078-3 [doi]
Stefano, V. De ; Rocca, B. ; Tosetto, A. ; Soldati, D. ; Petrucci, G. ; Beggiato, E. ; Bertozzi, I. ; Betti, S. ; Carli, G. ; Carpenedo, M. ; Cattaneo, D. ; Cavalca, V. ; Dragani, A. ; Elli, E. ; Finazzi, G. ; Iurlo, A. ; Lanzarone, G. ; Lissandrini, L. ; Palandri, F. ; Paoli, C. ; Rambaldi, A. ; Ranalli, P. ; Randi, M. L. ; Ricco, A. ; Rossi, E. ; Ruggeri, M. ; Specchia, G. ; Timillero, A. ; Turnu, L. ; Vianelli, N. ; Vannucchi, A. M. ; Rodeghiero, F. ; Patrono, C. / The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. In: Blood Cancer Journal. 2018 ; Vol. 8, No. 6. pp. 3.
@article{e1a1373b9510474fa22a0021876aedc6,
title = "The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting",
abstract = "Once-daily (od), low-dose aspirin (75-100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.",
author = "Stefano, {V. De} and B. Rocca and A. Tosetto and D. Soldati and G. Petrucci and E. Beggiato and I. Bertozzi and S. Betti and G. Carli and M. Carpenedo and D. Cattaneo and V. Cavalca and A. Dragani and E. Elli and G. Finazzi and A. Iurlo and G. Lanzarone and L. Lissandrini and F. Palandri and C. Paoli and A. Rambaldi and P. Ranalli and Randi, {M. L.} and A. Ricco and E. Rossi and M. Ruggeri and G. Specchia and A. Timillero and L. Turnu and N. Vianelli and Vannucchi, {A. M.} and F. Rodeghiero and C. Patrono",
note = "LR: 20190124; JID: 101568469; 2018/02/15 00:00 [received]; 2018/04/03 00:00 [accepted]; 2018/03/23 00:00 [revised]; 2018/06/09 06:00 [entrez]; 2018/06/09 06:00 [pubmed]; 2018/06/09 06:00 [medline]; epublish",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/s41408-018-0078-3 [doi]",
language = "English",
volume = "8",
pages = "3",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

AU - Stefano, V. De

AU - Rocca, B.

AU - Tosetto, A.

AU - Soldati, D.

AU - Petrucci, G.

AU - Beggiato, E.

AU - Bertozzi, I.

AU - Betti, S.

AU - Carli, G.

AU - Carpenedo, M.

AU - Cattaneo, D.

AU - Cavalca, V.

AU - Dragani, A.

AU - Elli, E.

AU - Finazzi, G.

AU - Iurlo, A.

AU - Lanzarone, G.

AU - Lissandrini, L.

AU - Palandri, F.

AU - Paoli, C.

AU - Rambaldi, A.

AU - Ranalli, P.

AU - Randi, M. L.

AU - Ricco, A.

AU - Rossi, E.

AU - Ruggeri, M.

AU - Specchia, G.

AU - Timillero, A.

AU - Turnu, L.

AU - Vianelli, N.

AU - Vannucchi, A. M.

AU - Rodeghiero, F.

AU - Patrono, C.

N1 - LR: 20190124; JID: 101568469; 2018/02/15 00:00 [received]; 2018/04/03 00:00 [accepted]; 2018/03/23 00:00 [revised]; 2018/06/09 06:00 [entrez]; 2018/06/09 06:00 [pubmed]; 2018/06/09 06:00 [medline]; epublish

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Once-daily (od), low-dose aspirin (75-100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.

AB - Once-daily (od), low-dose aspirin (75-100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.

U2 - 10.1038/s41408-018-0078-3 [doi]

DO - 10.1038/s41408-018-0078-3 [doi]

M3 - Article

VL - 8

SP - 3

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 6

ER -